Stratenity POV, Global Health Industry Scan

Delivering outcomes when the money is politically fragile

The core challenge in global health is a widening gap between need and financing, compounded by donor concentration. In 2025 the restructuring of US foreign assistance, historically the largest single source at roughly $12 billion per year for global health, disrupted HIV, malaria, and maternal-health programs that ministries had built around it. Roughly a quarter of low-income-country health financing has depended on external donors, which makes program continuity hostage to politics far from the patient.

• Donor concentration is a structural risk: PEPFAR alone has supported HIV treatment for over 20 million people.
• Out-of-pocket spending still pushes an estimated 344 million people into extreme poverty annually, per WHO.
• Universal health coverage remains off track: about half the world's population lacks full coverage of essential services.

From donor dependence to domestic and blended financing

Sustainability means shifting from vertical donor programs toward domestic resource mobilization and blended finance. The Abuja Declaration target of 15 percent of government budget spent on health is met by only a handful of African Union states. Cost-effectiveness must be measured rigorously: the disability-adjusted life year, or DALY, is the standard unit, and the WHO-CHOICE benchmark historically treated interventions under one to three times GDP per capita per DALY averted as cost-effective.

A worked example: a malaria program averting 100,000 DALYs at a total cost of $4 million spends $40 per DALY averted, far below one times GDP per capita in most endemic countries, making it among the most cost-effective spending available. Losing donor funding mid-cycle strands that investment and reverses gains.

The health-worker shortage is the binding constraint

The WHO projects a shortfall of roughly 10 million health workers by 2030, concentrated in low- and lower-middle-income countries. No amount of financing or technology delivers outcomes without frontline workers, yet high-income countries actively recruit from the very systems facing the deepest gaps, driving a brain drain the WHO Global Code of Practice was written to curb.

• Community health workers extend reach affordably, but they need pay, supervision, and supplies, not just training.
• Task-shifting and task-sharing, moving defined tasks to less specialized cadres, expands capacity where physicians are scarce.
• Retention economics matter: attrition of trained workers erases years of investment and destabilizes programs.

Digital health that strengthens systems rather than fragmenting them

Global health has a pilot-graveyard problem: thousands of digital-health pilots that never scaled or interoperated. The WHO SMART Guidelines and the OpenHIE architecture, with standards like HL7 FHIR and DHIS2 as the near-universal health-information system, exist to prevent that fragmentation. AI holds promise in diagnostics, such as computer-aided TB detection from chest X-rays, but requires validation on local populations, not just high-income training data.

• Standardize on interoperable platforms (DHIS2, FHIR, OpenHIE) rather than commissioning bespoke, siloed tools.
• Validate AI diagnostics on representative local data; models trained elsewhere can systematically misperform.
• Ensure data sovereignty and privacy: patient data governance must respect national law and community consent.

A layered regime from global treaty to national regulator

Global health governance spans the International Health Regulations (2005), amended in 2024 to add a pandemic-emergency tier, and the WHO Pandemic Agreement adopted in 2025. Product quality runs through WHO Prequalification and the Global Benchmarking Tool for national regulatory authorities. Research ethics follow the Declaration of Helsinki and CIOMS guidelines, with local ethics-committee approval required. The Nagoya Protocol governs pathogen and genetic-resource sharing.

• IHR (2005): countries must build core surveillance and response capacities and report events of international concern.
• WHO Prequalification: a gate for donor procurement of medicines, vaccines, and diagnostics.
• Research ethics: informed consent and independent ethics review are non-negotiable, especially in vulnerable populations.

The outcome is measured at the last mile, not the warehouse

In global health the customer is the patient and the health system, and reliability is measured in continuity of care. A treatment gap in antiretroviral therapy risks viral rebound and resistance; a vaccine cold-chain break renders doses useless. The 90-90-90 and now 95-95-95 HIV targets, where 95 percent are diagnosed, 95 percent of those on treatment, and 95 percent of those virally suppressed, show how outcomes chain together and how one weak link collapses the whole cascade.

• Treatment continuity: interruptions in ART or TB regimens drive resistance and waste prior spending.
• Cold-chain integrity: temperature excursions destroy vaccine efficacy invisibly until an outbreak reveals it.
• Last-mile delivery, not central procurement, is where most programs fail; measure availability at the clinic, not the port.

A crowded ecosystem that must align behind country plans

Global health runs on a dense partnership ecosystem: Gavi for immunization, the Global Fund for HIV, TB, and malaria, WHO, UNICEF, national ministries, and thousands of implementing NGOs. The risk is fragmentation, with parallel programs that bypass and weaken national systems. The principle of country ownership, embodied in the International Health Partnership and one-plan approaches, aligns partners behind a single national strategy.

• Align funding behind the national health strategy rather than creating parallel donor silos.
• Pooled procurement (Gavi, Global Fund) lowers commodity prices and stabilizes supply for small markets.
• Integrate vertical disease programs into primary health care to avoid duplicated infrastructure.

Allocation decisions as governed, evidence-backed artifacts

Stratenity's operating view is that a resource-allocation decision is an artifact carrying its cost-per-DALY evidence, its data sources, its assumptions, and its version history. When funding is shrinking and politically contested, the ministries and funders that survive are those who can defend every dollar on transparent, explainable cost-per-outcome reasoning rather than activity counts. Governance here is not bureaucracy; it is the mechanism that protects the most cost-effective, life-saving programs when budgets are cut and every choice must be justified.

Five strategic moves for global-health leaders

• Build a domestic-financing transition plan now, targeting the Abuja 15 percent benchmark to reduce donor dependence.
• Rank every program by cost per DALY averted and protect the most cost-effective interventions from budget cuts first.
• Invest in the community health workforce with real pay and supervision, not one-off training.
• Consolidate onto interoperable digital platforms (DHIS2, FHIR) and retire siloed pilots.
• Align all partners behind one national health strategy to end parallel-program fragmentation.

Five levers, each with a target metric

• Domestic-financing shift: raise government health spending toward 15 percent of the national budget within the medium-term plan.
• Cost-effectiveness triage: retain only interventions under 1x GDP per capita per DALY averted where budgets are constrained.
• Supply-chain strengthening: cut commodity stockout rates below 5 percent at the last-mile facility level.
• Workforce expansion: grow the deployed community-health-worker density toward WHO staffing thresholds per 10,000 population.
• Treatment-cascade closure: reach the 95-95-95 HIV targets, driving viral suppression above 95 percent of those on treatment.

Related reading

Put this sector view to work with the cross-cutting Stratenity frameworks.